Stay updated with breaking news from Eric Schadt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sema4 (NASDAQ:SMFR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal […]
Sema4 Holdings Corp (NASDAQ:SMFR – Get Rating)’s stock price traded down 6.2% during trading on Monday . The company traded as low as $2.81 and last traded at $2.89. 76,128 shares were traded during trading, a decline of 96% from the average session volume of 1,707,424 shares. The stock had previously closed at $3.08. Several […]
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
Sema4 (NASDAQ:SMFR – Get Rating) announced its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.09, MarketWatch Earnings reports. Sema4 updated its FY 2022 guidance to EPS. NASDAQ SMFR traded up $0.05 during mid-day trading on Tuesday, hitting $2.70. The […]
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.